Holen Sie sich die Stockscreener-App
14.97
1.45%
-0.22
Handel nachbörslich:
14.70
-0.27
-1.80%
Schlusskurs vom Vortag:
$15.19
Offen:
$15.19
24-Stunden-Volumen:
2.40M
Relative Volume:
0.38
Marktkapitalisierung:
$1.40B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-313.94M
KGV:
-4.2698
EPS:
-3.506
Netto-Cashflow:
$-284.57M
1W Leistung:
+24.13%
1M Leistung:
+51.67%
6M Leistung:
+87.83%
1J Leistung:
+179.81%
1-Tages-Spanne:
$14.69
$15.39
1-Wochen-Bereich:
$12.27
$15.71
52-Wochen-Spanne:
$1.50
$15.71
Replimune Group Inc Stock (REPL) Company Profile
Firmenname
Replimune Group Inc
Sektor
Branche
Telefon
(781) 222-9600
Adresse
500 UNICORN PARK, WOBURN, MA
Compare REPL vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
14.97 | 1.43B | 0 | -313.94M | -284.57M | -3.506 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2026-04-13 | Herabstufung | H.C. Wainwright | Buy → Sell |
| 2026-04-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2026-04-13 | Herabstufung | Jefferies | Buy → Hold |
| 2026-04-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-04-13 | Herabstufung | Wedbush | Outperform → Neutral |
| 2026-04-10 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-11-03 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2025-10-27 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-10-20 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | Hochstufung | Wedbush | Neutral → Outperform |
| 2025-09-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | Herabstufung | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-23 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-06-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2023-04-17 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-17 | Eingeleitet | BTIG Research | Buy |
| 2020-11-02 | Eingeleitet | Jefferies | Buy |
| 2020-10-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-09-04 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-25 | Eingeleitet | Wedbush | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-08-14 | Eingeleitet | JP Morgan | Overweight |
| 2018-08-14 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Replimune Group Inc Aktie (REPL) Neueste Nachrichten
Replimune Raises $150 Million To Fund TUDRIQEV Launch And Confirmatory Trial - Pulse 2.0
REPL SWOT Analysis: FDA Approval of TUDRIQEV Marks a Turning Point - GuruFocus
REPL Ignites On Doctor Fury Against FDA’s Melanoma Drug Snub — Health Sec Steps Back - Stocktwits
Replimune Group (NASDAQ:REPL) Releases Quarterly Earnings Results - marketbeat.com
REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85% - Stocktwits
Form 8K Replimune Group Inc For: 7 August By Investing.com - Investing.com Nigeria
Replimune Group, Inc. Files For Mixed Shelf Size Not Disclosed - TradingView
Replimune (NASDAQ: REPL) secures FDA accelerated approval and raises $141M - Stock Titan
Replimune Group (REPL): Ridgeback Capital now reports 3.5% ownership stake - Stock Titan
Why Is Replimune (NASDAQ:REPL) Drawing Attention After Its Oncology Approval? - Kalkine Media
Replimune Group Releases Q1 2027 Financial Results - AlphaStreet
2026-08-14 | REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:REPL | Press Release - Stockhouse
Replimune Group stock may move 5.6% on earnings release By Investing.com - Investing.com Nigeria
DEADLINE ALERT for BZAI, BABA, ALAR, and REPL: The Law - GlobeNewswire
REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action LawsuitInvestors Should Contact The Gross Law Firm - WBOC TV
Replimune Group stock may move 5.6% on earnings release - Investing.com
Deadline Alert: Replimune Group, Inc. (REPL) Shareholders - GlobeNewswire
Replimune Q1 EPS $(0.72) beats estimate; FDA approves TUDRIQEV - scanx.trade
Form 8K Replimune Group Inc For: 14 August By Investing.com - Investing.com Australia
Replimune Reports Fiscal First Quarter 2027 Financial Results And Provides Corporate Update - TradingView
Replimune Fiscal Q1 Net Loss Narrows - marketscreener.com
REPL: FDA approval of TUDRIQEV and new financing drive launch and extend cash runway for over a year - TradingView
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update - The Manila Times
Replimune Reports $69.8 Million First-Quarter Loss After TUDRIQEV FDA Approval - Quiver Quantitative
REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug? - Stocktwits
REPL SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on - GlobeNewswire
Replimune Group (REPL) Wins FDA Approval For Advanced Melanoma Treatment - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Group Inc. (REPL) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Gro - The National Law Review
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. LawsuitREPL - Morningstar
Replimune Group Stock Short Interest Rises to 57.95% - Moomoo
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - PR Newswire
Replimune Group (NASDAQ:REPL) Insider Sells 11,447 Shares of Stock - marketbeat.com
Emily Luisa Hill Sells 11,448 Shares of Replimune Group (NASDAQ:REPL) Stock - marketbeat.com
Insider Selling: Replimune Group (NASDAQ:REPL) CEO Sells 39,341 Shares - marketbeat.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Replimune Group Inc. (REPL) And Encourages Shareholders to Reach Out - ACCESS Newswire
Replimune group CEO Sushil Patel sells $510,252 in stock By Investing.com - Investing.com Nigeria
Replimune CFO Emily Hill sells $148,480 in shares for tax withholding - Investing.com Nigeria
Replimune group CEO Sushil Patel sells $510,252 in stock - Investing.com
Replimune Group Chief Executive Officer Sold Shares Worth Over $510K - TradingView
What happened at FDA? Replimune approval raises questions - The Cancer Letter
REPL Class Action ReminderRobbins LLP Reminds Investors - GlobeNewswire
Levi & Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026REPL - PR Newswire
Cantor Fitzgerald reiterates Replimune stock rating on launch potential By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Replimune stock rating on launch potential - Investing.com India
REPL INVESTOR NOTICE: Replimune Group, Inc. Investors with - GlobeNewswire
Replimune Group (NASDAQ:REPL) Sets New 12-Month HighHere's Why - marketbeat.com
Finanzdaten der Replimune Group Inc-Aktie (REPL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):